Coya Therapeutics

Coya Therapeutics received U.S. Patent 12,312,389 B2 covering methods for producing highly stable liquid formulations of IL-2 (aldesleukin), strengthening its intellectual property portfolio.

Coya Therapeutics is advancing its regulatory T cell-derived exosome (Treg exosome) platform with plans to initiate GMP manufacturing of clinical batches by Q4 2025, positioning it for first-in-human trials.

Coya Therapeutics is set to initiate a Phase 2b trial for Coya-302 in 2025, an innovative approach to treating amyotrophic lateral sclerosis (ALS) by enhancing regulatory T cells (Tregs).

Coya Therapeutics reports that five of eight planned patients have been enrolled in a Phase 1 study evaluating low-dose IL-2 and CTLA4-Ig combination for frontotemporal dementia (FTD).

A JAMA Neurology study reveals that deferiprone, while successfully reducing brain iron accumulation, unexpectedly accelerated cognitive decline in early Alzheimer's disease patients.

Semaglutide, a GLP-1 receptor agonist, demonstrates improved kidney function in overweight/obese patients with albuminuric chronic kidney disease without diabetes.

Coya Therapeutics' COYA-301 phase II trial in Alzheimer's patients showed promise with monthly dosing, but more frequent bi-weekly dosing led to exhausted regulatory T cells and no clinical benefits.

Coya Therapeutics announced results from a Phase 2 trial of low-dose interleukin-2 (LD IL-2) in mild to moderate Alzheimer's Disease (AD).

The exosome market is experiencing rapid growth, driven by advancements in liquid biopsy, precision medicine, and regenerative medicine.

Several clinical trials are underway for sporadic ALS, targeting TDP-43 pathology, STMN2 expression, and neuroinflammation.